SCHEMBL12099792

SCHEMBL12099792

O=Cc1ncccc1N1CCC(Oc2ccc(Cl)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 4/20 0.39
PROKR1 Q8TCW9 4/20 0.39
EPHX2 P34913 1/20 0.39
HRH1 P35367 1/20 0.39
CCR3 P51677 1/20 0.39
KCNH2 Q12809 1/20 0.39
FFAR1 O14842 3/20 0.38
SCN9A Q15858 1/20 0.38
SCD O00767 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPK14 Q16539 1/20 0.38
CNR1 P21554 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
CHRM4 P08173 1/20 0.37
ACACB O00763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12099623 0.84 MAPK14 (0.42) FPR2PROKR1EPHX2FFAR1SCN9A
SCHEMBL12099786 0.84 CHRM4 (0.42) FPR2PROKR1FFAR1MAPK14CHRM4
SCHEMBL12099739 0.81 EPHX2 (0.45) FPR2PROKR1EPHX2HRH1CCR3
SCHEMBL12100122 0.81 FPR2 (0.43) FPR2PROKR1KCNH2FFAR1SCN9A
SCHEMBL12099671 0.81 FPR2 (0.43) FPR2PROKR1KCNH2FFAR1SCN9A
SCHEMBL12100367 0.79 FPR2 (0.44) FPR2PROKR1KCNH2FFAR1SCN9A
SCHEMBL27666187 0.79 CHRM4 (0.48) CHRM4
SCHEMBL12100080 0.78 ACACB (0.45) FPR2PROKR1FFAR1SCN9AMAPK14
SCHEMBL12099555 0.78 FPR2 (0.47) FPR2PROKR1HRH1CCR3FFAR1
SCHEMBL12100063 0.77 FFAR1 (0.39) FPR2PROKR1EPHX2HRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051296-B2 Aryl carboxamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-06-09 US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN1A, SCN2B FPR2 419/4885PROKR1 3885/4885EPHX2 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.